Pre-made Dupilumab benchmark antibody ( Whole mAb, anti-IL4R therapeutic antibody, Anti-CD124 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-158

Pre-Made Dupilumab biosimilar, Whole mAb, Anti-IL4R Antibody: Anti-CD124 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody used for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-158-1mg 1mg 3090
GMP-Bios-ab-158-10mg 10mg Inquiry
GMP-Bios-ab-158-100mg 100mg Inquiry
GMP-Bios-ab-158-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Dupilumab biosimilar, Whole mAb, Anti-IL4R Antibody: Anti-CD124 therapeutic antibody
INN Name Dupilumab
TargetIL4R
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure6wgb:AB:CD/6wgj:AB:CD:EF/6wgk:AB:CD:EF:GH/6wgl:AB/6wg8:AB
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesAimmune Therapeutics;Regeneron Pharmaceuticals;Sanofi
Conditions ApprovedAsthma;Atopic dermatitis;Nasal polyps
Conditions ActiveChronic obstructive pulmonary disease;Eosinophilic oesophagitis;Grass pollen hypersensitivity;Peanut hypersensitivity;Urticaria
Conditions DiscontinuedAllergic asthma
Development TechVelocImmune Mouse